Clearmind Medicine Announces Collaboration with CTS Ltd., a Leading Pharmaceutical and Consumer Products Company
2023年8月14日 - 9:25PM
Clearmind Medicine Inc. (Nasdaq, CSE: CMND), (FSE: CWY)
(“Clearmind” or the "Company"), a biotech company focused on
discovery and development of novel psychedelic-derived therapeutics
to solve major under-treated health problems, today announced that
the Company and CTS Ltd. ("CTS") have agreed to collaborate on
product development.
CTS is a leading pharmaceutical and consumer
products company in Israel. Founded in 1921, CTS focuses on
solutions that have clinically proven efficacy and safety,
supporting the health of people. In addition, CTS imports,
registers, markets, and distributes healthcare products of leading
global pharmaceutical companies across Israel.
As part of the collaboration, Clearmind Medicine
will have access to the CTS’ state-of-the-art facilities, allowing
it to expand its research and development capabilities.
Furthermore, the collaboration provides Clearmind access to CTS’
global networks and industry connections, the ability to leverage
CTS’ expertise in manufacturing and marketing, as well as benefit
from CTS’ vast industry experience and guidance, ensuring that the
Company's treatments meet the highest standards of quality, safety,
and efficacy.
"We are honored to collaborate with such a
prominent pharmaceutical company. CTS’ support and expertise will
be invaluable as we advance our research and development efforts in
psychedelic-based therapeutics. This significant milestone
recognizes Clearmind Medicine's innovative approach as well as
highlights the growing interest in the field of psychedelic-based
therapies within the pharmaceutical industry. Together, we have the
opportunity to revolutionize mental health treatments and provide
much-needed relief to individuals suffering from a range of mental
health conditions," said Clearmind’s Chief Executive Officer, Dr.
Adi Zuloff-Shani.
About Clearmind Medicine Inc.
Clearmind is a psychedelic pharmaceutical biotech
company focused on the discovery and development of novel
psychedelic-derived therapeutics to solve widespread and
underserved health problems, including alcohol use disorder. Its
primary objective is to research and develop psychedelic-based
compounds and attempt to commercialize them as regulated medicines,
foods or supplements.
The Company’s intellectual portfolio currently
consists of fourteen patent families. The Company intends to seek
additional patents for its compounds whenever warranted and will
remain opportunistic regarding the acquisition of additional
intellectual property to build its portfolio.
Shares of Clearmind are listed for trading on
Nasdaq and the Canadian Securities Exchange under the symbol "CMND"
and the Frankfurt Stock Exchange under the symbol “CWY.”
For further information
visit: https://www.clearmindmedicine.com or contact:
Investor Relations
invest@clearmindmedicine.com Telephone: (604) 260-1566 US:
CMND@crescendo-ir.com
General Inquiries
Info@Clearmindmedicine.com www.Clearmindmedicine.com
Forward-Looking Statements:
This press release contains “forward-looking statements” within
the meaning of the Private Securities Litigation Reform Act and
other securities laws. Words such as “expects,” “anticipates,”
“intends,” “plans,” “believes,” “seeks,” “estimates” and similar
expressions or variations of such words are intended to identify
forward-looking statements. For example, the Company is using
forward-looking statements when it discusses potential future
collaboration with CTS. Forward-looking statements are not
historical facts, and are based upon management’s current
expectations, beliefs and projections, many of which, by their
nature, are inherently uncertain. Such expectations, beliefs and
projections are expressed in good faith. However, there can be no
assurance that management’s expectations, beliefs and projections
will be achieved, and actual results may differ materially from
what is expressed in or indicated by the forward-looking
statements. Forward-looking statements are subject to risks and
uncertainties that could cause actual performance or results to
differ materially from those expressed in the forward-looking
statements. For a more detailed description of the risks and
uncertainties affecting the Company, reference is made to the
Company’s reports filed from time to time with the Securities and
Exchange Commission (“SEC”), including, but not limited to, the
risks detailed in the Company’s annual report on Form 20-F filed
with the SEC on February 6, 2023. Forward-looking statements speak
only as of the date the statements are made. The Company assumes no
obligation to update forward-looking statements to reflect actual
results, subsequent events or circumstances, changes in assumptions
or changes in other factors affecting forward-looking information
except to the extent required by applicable securities laws. If the
Company does update one or more forward-looking statements, no
inference should be drawn that the Company will make additional
updates with respect thereto or with respect to other
forward-looking statements. References and links to websites have
been provided as a convenience, and the information contained on
such websites is not incorporated by reference into this press
release. Clearmind is not responsible for the contents of
third-party websites.
Clearmind Medicine (NASDAQ:CMND)
過去 株価チャート
から 4 2024 まで 5 2024
Clearmind Medicine (NASDAQ:CMND)
過去 株価チャート
から 5 2023 まで 5 2024